Director / PDMR Shareholding

 12th Jul 2016

EKF Diagnostics Holdings plc

(“EKF” or the “Company”)

 

Notification of transactions by Persons Discharging Managerial Responsibilities

and persons closely associated with them

 

EKF Diagnostics Holdings plc (AIM: EKF) announces that on 11 July 2016, the Company was notified that Harwood Capital LLP ("Harwood") acquired 3,057,940 ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares") as investment manager to North Atlantic Smaller Companies Investment Trust PLC ("NAIT"). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in NAIT.

 

Following the above transaction, which was completed on 8 July 2016 at a price of 14.9653 pence per share, NAIT's interest is now in 78,100,000 Ordinary Shares, representing 16.82% of the Company's issued share capital. The interests of Oryx International Growth Fund Limited ("Oryx", whose investment adviser is Harwood) remains as previously disclosed in 40,000,000 Ordinary Shares, representing 8.62% of the Company's issued share capital. Mr Mills is also a director and shareholder in Oryx.

 

The total indirect beneficial interest of Mr Mills is, following the above transaction, therefore now in 118,100,000 Ordinary Shares, representing 25.44% of the Company's issued share capital.

 

 

EKF Diagnostics Holdings plc   

Tel: 029 2071 0570

Julian Baines, CEO 

 

Richard Evans, FD & COO

 

 

 

Panmure Gordon (UK) Limited

Tel: 020 7886 2500

Paul Fincham

 

Peter Steel

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

 

This notification is made in accordance with the requirements of the EU Market Abuse Regulation. Further details:

 

Initial notification / amendment: Initial

Ordinary Shares Identification Code: ISIN GB0031509804

Aggregated information: N/A

Place of the transaction: London Stock Exchange, AIM (XLON)